Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003967 · ClinicalTrials.gov registry record · Phase 1
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
A Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT00003967 is a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 24 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00003967, a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of topotecan plus etoposide in treating patients who have recurrent ovarian cancer, peritoneal cancer, or fallopian tube cancer.
Conditions Studied
Interventions
- DRUG etoposide
- DRUG topotecan hydrochloride
Study Locations (6)
Ohio
- Ireland Cancer Center - Cleveland
- Cleveland Clinic Taussig Cancer Center - Cleveland
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
Iowa
- Holden Comprehensive Cancer Center at The University of Iowa - Iowa City
Maryland
- Mercy Medical Center, Inc. - Baltimore
New Jersey
- Cooper Hospital/University Medical Center - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1999-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003967
The ClinicalTrials.gov registry entry for NCT00003967 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which etoposide is the first listed.
NCT00003967 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Iowa, Maryland.
Frequently Asked Questions
What is clinical trial NCT00003967 about?
NCT00003967 is a clinical study titled "Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of topotecan plus etoposide in treating patients who have recurrent ovari...
What is the current status of trial NCT00003967?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1999-09.
What conditions does trial NCT00003967 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT00003967?
The interventions under investigation include: etoposide (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003967?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003967 being conducted?
This trial has 6 study locations across Iowa, Maryland, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.